Gleevec and Letairis drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Gleevec (imatinib mesylate) and Letairis (ambrisentan). Common drug interactions include death among females and infection among males.

The phase IV clinical study analyzes what interactions people have when they take Gleevec and Letairis. It is created by eHealthMe based on reports of 19 people who take the same drugs from the FDA, and is updated regularly.

What is Gleevec?

Gleevec has active ingredients of imatinib mesylate. It is often used in chronic myelogenous leukemia (cml). eHealthMe is studying from 35,415 Gleevec users. Check the latest studies of Gleevec.

What is Letairis?

Letairis has active ingredients of ambrisentan. It is often used in pulmonary hypertension. eHealthMe is studying from 94,041 Letairis users. Check the latest studies of Letairis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

19 people who take Gleevec and Letairis together, and have interactions are studied.

What are the common drug interactions of Gleevec and Letairis, by gender? *:

female:

Death
Dyspnoea (difficult or laboured respiration)
Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
Fluid retention (an abnormal accumulation of fluid in the blood)
Hemiplegia (paralysis of one side of the body)
Malignant melanoma (skin cancer rises from melancytes)
Neoplasm malignant (cancer tumour)
Speech disorder
Syncope (loss of consciousness with an inability to maintain postural tone)
White blood cell count decreased

male:

Infection
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Swelling face
Vomiting
Hospitalisation
Influenza
Medical device complication
Pyrexia (fever)
Surgery
Dyspnoea (difficult or laboured respiration)

What are the common drug interactions of Gleevec and Letairis, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Hospitalisation
Infection
Influenza
Medical device complication
Pyrexia (fever)
Surgery

20-29:

n/a

30-39:

n/a

40-49:

Cardiac failure congestive
Renal failure (kidney dysfunction)
Sepsis (a severe blood infection that can lead to organ failure and death)
Syncope (loss of consciousness with an inability to maintain postural tone)

50-59:

Brain abscess
Cardio-respiratory arrest (sudden dysfunction of heart and lungs)
Death
Meningitis (inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges)
Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)

60+:

Death
Dyspnoea (difficult or laboured respiration)
Neoplasm malignant (cancer tumour)
Pulmonary oedema (fluid accumulation in the lungs)
Right ventricular failure (right half of the heart fails to work)
White blood cell count decreased
Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
Fluid retention (an abnormal accumulation of fluid in the blood)
Hemiplegia (paralysis of one side of the body)
Speech disorder

What are the existing conditions these people have? *

Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 11 people, 57.89%
Systemic Sclerosis (an autoimmune or connective tissue disease. it is characterized by thickening of the skin): 1 person, 5.26%
Gastric Cancer (stomach cancer): 1 person, 5.26%
Cor Pulmonale Chronic (long lasting enlargement of the right ventricle of the heart): 1 person, 5.26%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Gleevec and Letairis?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously